ExCyte Biopharma Ltd
Clinical trials sponsored by ExCyte Biopharma Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New kidney drug YK012 enters first human tests Results expected Dec 2026 (estimated)
- New drug YK012 tested in early leukemia trial Results expected Dec 2026 (estimated)
- New bispecific antibody YKST02 enters human trials for Hard-to-Treat myeloma Results expected Dec 2026 (estimated)
- New lupus drug YK012 enters human trials – hope for patients? Results expected Jun 2027 (estimated)
-
New antibody drug aims to outsmart Treatment-Resistant myeloma
Disease control Not yet recruitingThis phase 2 trial tests an investigational drug called YKST02 in adults with multiple myeloma that has relapsed or stopped responding to prior treatments. YKST02 is a bispecific antibody designed to bind both myeloma cells and immune T cells, potentially helping the immune syste…
Phase 2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New antibody drug aims to tame Hard-to-Treat kidney disease
Disease control Not yet recruitingThis early-stage trial tests a new drug called YK012 in 66 adults with a severe form of kidney disease called primary membranous nephropathy that has not responded to standard treatments. YK012 is a bispecific antibody designed to reduce the immune system's attack on the kidneys.…
Phase 1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC